Back to Browse Journals » Neuropsychiatric Disease and Treatment » Volume 5

Aripiprazole in the treatment of Huntington’s disease: a case series

Authors Andrea Ciammola, Jenny Sassone, Clarissa Colciago, Niccolò E Mencacci, Barbara Poletti, et al

Published Date November 2008 Volume 2009:5 Pages 1—4

DOI http://dx.doi.org/10.2147/NDT.S4165

Published 25 November 2008

Andrea Ciammola1, Jenny Sassone1, Clarissa Colciago1, Niccolò E Mencacci1, Barbara Poletti1, Andrea Ciarmiello2, Ferdinando Squitieri3, Vincenzo Silani1

1Department of Neurology and Laboratory of Neuroscience, “Dino Ferrari” Centre, University of Milan Medical School – IRCCS Istituto Auxologico Italiano, Milano, Italy; 2Unit of Nuclear Medicine, S. Andrea Hospital, La Spezia, Italy; 3Neurogenetics Unit, IRCCS Neuromed, Pozzilli (IS), Italy

Objectives: The aim of the study was to describe the effects of aripiprazole, a new atypical antipsychotic drug that acts as a partial dopamine agonist on motor, behavioral and cognitive functions in patients with genetically confirmed Huntington’s disease (HD).

Methods and results: Three HD patients were evaluated for Unified Huntington Disease Rating Scale part I and II and Beck Depression Inventory at baseline, after two months and one-year treatment. Aripiprazole effectively controlled involuntary movements and psychiatric symptoms, with effects on cognitive functions.

Conclusions: Our case reports suggest that aripiprazole is well tolerated, remarkably improving some of the motor and behavioral symptoms in patients affected by HD. Randomized, controlled, long-term studies are warranted.

Keywords: Huntington’s disease, aripiprazole, treatment, chorea

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

A histological evaluation and in vivo assessment of intratumoral near infrared photothermal nanotherapy-induced tumor regression

Green HN, Crockett SD, Martyshkin DV, Singh KP, Grizzle WE, Rosenthal EL, Mirov SB

International Journal of Nanomedicine 2014, 9:5093-5102

Published Date: 5 November 2014

Vincristine sulfate liposomal injection for acute lymphoblastic leukemia [Corrigendum]

Soosay Raj TA, Smith AM, Moore AS

International Journal of Nanomedicine 2013, 8:4705-4706

Published Date: 5 December 2013

Inhibition of A/Human/Hubei/3/2005 (H3N2) influenza virus infection by silver nanoparticles in vitro and in vivo

Xiang DX, Zheng Y, Duan W, Li XJ, Yin JJ, Shigdar S, O'Connor ML, Marappan M, Zhao XJ, Miao YQ, Xiang B, Zheng CL

International Journal of Nanomedicine 2013, 8:4103-4114

Published Date: 30 October 2013

Topical azithromycin or ofloxacin for endophthalmitis

Stewart MW, Stewart ML

Clinical Ophthalmology 2013, 7:35-38

Published Date: 31 December 2012

Corrigendum

Mizoguchi T, Ozaki M, Unoki K, Dake Y, Eto T, Arai M

Clinical Ophthalmology 2012, 6:1717-1718

Published Date: 26 October 2012

Injectable hydrogel as stem cell scaffolds from the thermosensitive terpolymer of NIPAAm/AAc/HEMAPCL

Lian S, Xiao Y, Bian QQ, Xia Y, Guo CF, Wang SG, Lang MD

International Journal of Nanomedicine 2012, 7:4893-4905

Published Date: 12 September 2012

Corrigendum

Sakai T, Kohzaki K, Watanabe A, Tsuneoka H, Shimadzu M

Clinical Ophthalmology 2012, 6:1035-1036

Published Date: 5 July 2012

Erratum

RA Kurt, K Gündüz

Clinical Ophthalmology 2010, 4:981-982

Published Date: 6 September 2010